Laurus Labs Strengthens Board, Boosts Pharma JV with €9.8M Investment

Laurus Labs's board has approved key changes, appointing two new independent directors and investing up to €9.8 million in its joint venture, KRKA Pharma Private Limited. The company also plans to close its German subsidiary, Laurus Generics GmbH.

Board Appointments

The company announced the appointment of Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors. Their five-year terms begin July 2, 2026. Director Mrs. Aruna Bhinge is set to retire on July 6, 2026.

Investment in Pharma Joint Venture

Laurus Labs will invest up to €9.8 million in KRKA Pharma Private Limited, its joint venture with Krka. This funding is designated for capital expenditure (capex) to expand manufacturing facilities.

Closure of German Subsidiary

In a move to streamline operations, Laurus Labs will voluntarily close its German subsidiary, Laurus Generics GmbH. The company reported nil turnover for FY2026, making the unit non-material to Laurus Labs's overall business.

Background on JV and Subsidiary

The KRKA Pharma joint venture was formed in January 2024 with Slovenian company Krka to develop products for Indian and other non-EU markets. Laurus Generics GmbH, established in 2019, was a wholly-owned subsidiary aimed at supplying generic medicines in European countries.

Operational Context

Laurus Labs operates within a competitive Indian pharmaceutical market, alongside major players like Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Cipla, and Divi's Laboratories. These peers also focus on API manufacturing, finished dosage forms, and global expansion. For FY2026, Laurus Generics GmbH reported nil turnover and a net worth of €1,053,091, while KRKA Pharma Private Limited had a target turnover of INR 10.47 million. The investment in KRKA Pharma is anticipated for completion in FY2026-27.

What to Watch

Investors will monitor shareholder approval for the new director appointments. The timely completion of the €9.8 million investment in KRKA Pharma JV, planned for FY2026-27, and the finalization of the German subsidiary's closure, subject to regulatory approval, are also key points to track.